

Muhammad S Beg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4193597/publications.pdf>

Version: 2024-02-01

99
papers

2,806
citations

331670

21
h-index

189892

50
g-index

100
all docs

100
docs citations

100
times ranked

5187
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal Experience With and Impressions of COVID-19-Related Clinical Research Changes. JCO Oncology Practice, 2022, 18, e98-e107.	2.9	8
2	Time-Related Burdens of Cancer Care. JCO Oncology Practice, 2022, 18, 245-246.	2.9	19
3	Association between environmental quality index and young onset colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 75-75.	1.6	0
4	Association between Environmental Quality Index and metastatic pancreatic cancer.. Journal of Clinical Oncology, 2022, 40, 521-521.	1.6	0
5	Can stereotactic ablative radiotherapy for oligometastatic pancreatic cancer help avoid perpetual chemotherapy and improve outcomes?. Journal of Clinical Oncology, 2022, 40, 571-571.	1.6	1
6	Patient-reported outcomes (PROs) in pancreatic cancer clinical trials (CTs).. Journal of Clinical Oncology, 2022, 40, 534-534.	1.6	0
7	Metastasectomy in colorectal cancer patients with concurrent lung and liver metastasis: Trends in utilization and impact on survival.. Journal of Clinical Oncology, 2022, 40, 53-53.	1.6	0
8	A phase 1b/2, open-label study of tivozanib in combination with durvalumab in subjects with advanced hepatocellular carcinoma (Deductive).. Journal of Clinical Oncology, 2022, 40, TPS499-TPS499.	1.6	0
9	The role of serial analysis of hepatocellular carcinoma via circulating tumor DNA in identification of new actionable alterations.. Journal of Clinical Oncology, 2022, 40, 478-478.	1.6	0
10	Disparities in place of death (PoD) in patients with gastrointestinal (GI) cancers.. Journal of Clinical Oncology, 2022, 40, 645-645.	1.6	0
11	Phase 1b/2 study of tivozanib in combination with durvalumab in subjects with advanced hepatocellular carcinoma (Deductive): Efficacy results in previously untreated patients.. Journal of Clinical Oncology, 2022, 40, 462-462.	1.6	1
12	Characteristics and trends in treatment utilization in young-onset cholangiocarcinoma.. Journal of Clinical Oncology, 2022, 40, 386-386.	1.6	0
13	Cancer Commons™ virtual tumor board program: A patient-centric advisory panel and real-world data registry.. Journal of Clinical Oncology, 2022, 40, 527-527.	1.6	0
14	A Propensity Score Analysis of Chemotherapy Use in Patients With Resectable Gallbladder Cancer. JAMA Network Open, 2022, 5, e2146912.	5.9	12
15	Twitter Conversations About Pancreatic Cancer by Health Care Providers and the General Public: Thematic Analysis. JMIR Cancer, 2022, 8, e31388.	2.4	5
16	QIM22-203: Randomized Trial of Implementing a Clinical Decision Support Tool for Automatic Selection of Payor-Mandated Biosimilar at Time of Prescribing. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, QIM22-203.	4.9	0
17	Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-Line Sorafenib in Randomized Controlled Trials. Gastrointestinal Tumors, 2022, 9, 19-26.	0.7	4
18	The pattern of brain metastasis in colorectal cancer: Efficacy of metastasectomy, chemotherapy.. Journal of Clinical Oncology, 2021, 39, 40-40.	1.6	2

#	ARTICLE	IF	CITATIONS
19	AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2021, 19, 1412-1421.	3.4	16
20	Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1165-1184.	1.6	54
21	Real-world treatment and outcomes of frontline chemotherapy in patients with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16249-e16249.	1.6	0
22	Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of KRAS. <i>Cells</i> , 2021, 10, 1275.	4.1	4
23	Clinicopathologic variables and outcomes in elderly colorectal cancer patients with microsatellite instability and multiple primary malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15516-e15516.	1.6	0
24	Increased neutrophil infiltration and lower prevalence of tumor mutation burden and microsatellite instability are hallmarks of RAS mutant colorectal cancers.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3563-3563.	1.6	0
25	Disparities in Characteristics, Access to Care, and Oncologic Outcomes in Young-Onset Colorectal Cancer at a Safety-Net Hospital. <i>JCO Oncology Practice</i> , 2021, 17, e614-e622.	2.9	3
26	Body composition measurements and overall survival in patients with resectable pancreatic adenocarcinoma receiving neoadjuvant chemotherapy: Analysis from SWOG S1505.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4131-4131.	1.6	0
27	A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4158-TPS4158.	1.6	0
28	GRECO-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with GC4711 in the treatment of unresectable or borderline resectable nonmetastatic pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4175-TPS4175.	1.6	4
29	Implementation of a Quality Improvement Project to Increase Access to Dietitian Services for Patients With Gastrointestinal Cancer in a Safety-Net Hospital System. <i>JCO Oncology Practice</i> , 2021, 17, e1048-e1054.	2.9	2
30	Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay. <i>Cancer Biology and Therapy</i> , 2021, 22, 455-464.	3.4	6
31	Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1904-1915.	4.1	15
32	Projected 30- day out-of-pocket costs and total spending on pancreatic enzyme replacement therapy under Medicare Part D. <i>Pancreatology</i> , 2021, 21, 1009-1010.	1.1	6
33	Clinical Efficiency and Safety Outcomes of Virtual Care for Oncology Patients During the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2021, 17, e1327-e1332.	2.9	20
34	Taking Tele Behind the Scenes: Remote Clinical Trial Monitoring Comes of Age During the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2021, 17, 577-579.	2.9	10
35	Sentiment analysis of tweets on prior authorization.. <i>Journal of Clinical Oncology</i> , 2021, 39, 322-322.	1.6	0
36	Impact of tumor location on effectiveness of first-line 5-FU-based palliative doublet chemotherapy in patients with metastatic gastroesophageal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 240-240.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Immunologic predictors of therapeutic response to neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDA) in SWOG S1505.. Journal of Clinical Oncology, 2021, 39, 419-419.	1.6	2
38	Current status and future perspectives on the Internet of Things in oncology. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.9	9
39	Age-dependent prognostic value of <i>KRAS</i> mutation in metastatic colorectal cancer. Future Oncology, 2021, 17, 4883-4893.	2.4	5
40	Liquid Biopsy for Cancer: Review and Implications for the Radiologist. Radiology, 2020, 294, 5-17.	7.3	52
41	Unique Patterns of Distant Metastases in HPV-Positive Head and Neck Cancer. Oncology, 2020, 98, 179-185.	1.9	20
42	Targeting TAM to Tame Pancreatic Cancer. Targeted Oncology, 2020, 15, 579-588.	3.6	4
43	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 4317-4345.	1.6	350
44	Reply to S. Boutayeb et al. JCO Oncology Practice, 2020, 16, 525-525.	2.9	1
45	Distinct Clinical Characteristics in Young-Onset Pancreatic Neuroendocrine Tumor. Cancers, 2020, 12, 2501.	3.7	10
46	Surgical Outcome Results From SWOG S1505. Annals of Surgery, 2020, 272, 481-486.	4.2	155
47	Racial/Ethnic Disparities and Survival Characteristics in Non-Pancreatic Gastrointestinal Tract Neuroendocrine Tumors. Cancers, 2020, 12, 2990.	3.7	3
48	Patterns of Care for Stage II-III Rectosigmoid Cancers in the United States, 2004-2015. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 311-318.	1.3	3
49	The association of lymphotoxin-beta receptor with the subsequent diagnosis of incident gastrointestinal cancer: results from the Dallas Heart Study. Journal of Gastrointestinal Oncology, 2020, 11, 36-44.	1.4	1
50	Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. Oncologist, 2020, 25, e1837-e1845.	3.7	21
51	DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden. Cell Reports Medicine, 2020, 1, 100034.	6.5	46
52	Stage-specific Conditional Survival Among Young (Age Below 50â€‰%) Versus Older (Age 50â€‰% and Above) Adults With Colorectal Cancer in the United States. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 526-530.	1.3	4
53	Improving the Time to Activation of New Clinical Trials at a National Cancer Instituteâ€œDesignated Comprehensive Cancer Center. JCO Oncology Practice, 2020, 16, e324-e332.	2.9	7
54	Telehealth and Palliative Care for Patients With Cancer: Implications of the COVID-19 Pandemic. JMIR Cancer, 2020, 6, e20288.	2.4	21

#	ARTICLE	IF	CITATIONS
55	Efficacy and Safety of Baviximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial. <i>Targeted Oncology</i> , 2019, 14, 541-550.	3.6	18
56	The Future of Wearable Technologies and Remote Monitoring in Health Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 115-121.	3.8	79
57	Self-reported Reasons and Patterns of Noninsurance Among Cancer Survivors Before and After Implementation of the Affordable Care Act, 2000-2017. <i>JAMA Oncology</i> , 2019, 5, e191973.	7.1	12
58	Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. <i>Head and Neck</i> , 2019, 41, 1928-1934.	2.0	21
59	NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 2601-2609.	7.0	37
60	Sociodemographic Disparities in the Receipt of Adjuvant Chemotherapy Among Patients With Resected Stage III Pancreatic Adenocarcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1292-1300.	4.9	15
61	Impact of Concurrent Medication Use on Pancreatic Cancer Survival—SEER-Medicare Analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 766-771.	1.3	32
62	Obesity is Independently Associated With Increased Risk of Hepatocellular Cancer-related Mortality. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 874-881.	1.3	164
63	Pasireotide for the treatment of refractory hypoglycaemia from malignant insulinoma. <i>Clinical Endocrinology</i> , 2018, 88, 341-343.	2.4	22
64	Developing rational combinations of immune checkpoint inhibitors and radiation therapy for gastrointestinal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 225-230.	1.4	2
65	Approach and management of checkpoint inhibitor-related immune hepatitis. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 220-224.	1.4	28
66	Palliative care and end-of-life health care utilization in elderly patients with pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 495-502.	1.4	32
67	Characteristics and impact of the most-cited palliative oncology studies from 1995 to 2016. <i>BMC Cancer</i> , 2018, 18, 1281.	2.6	3
68	Feasibility of Wearable Physical Activity Monitors in Patients With Cancer. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-10.	2.1	36
69	Staging systems of hepatocellular carcinoma: A review. <i>Indian Journal of Gastroenterology</i> , 2018, 37, 481-491.	1.4	88
70	Activity and pharmacology of homemade silver nanoparticles in refractory metastatic head and neck squamous cell cancer. <i>Head and Neck</i> , 2018, 41, E11-E16.	2.0	13
71	Pancreatic Cancer Metabolism: Molecular Mechanisms and Clinical Applications. <i>Current Oncology Reports</i> , 2018, 20, 56.	4.0	21
72	SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX versus gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS547-TPS547.	1.6	3

#	ARTICLE	IF	CITATIONS
73	Palliative care and end-of-life health utilization in elder patients with pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, 488-488.	1.6	1
74	Prescribing patterns for FOLFIRINOX in the real world.. Journal of Clinical Oncology, 2018, 36, 463-463.	1.6	0
75	Palliative care and end-of-life health care utilization of pancreatic cancer patients at an urban safety-net hospital.. Journal of Clinical Oncology, 2018, 36, 489-489.	1.6	0
76	Introduction of #PancChat: A novel Twitter platform to inform and engage the pancreatic cancer community.. Journal of Clinical Oncology, 2018, 36, 242-242.	1.6	2
77	Compliance with NCCN screening and chemoprevention recommendations among carriers of deleterious mutations in the adenomatous polyposis coli gene.. Journal of Clinical Oncology, 2018, 36, 571-571.	1.6	0
78	Effective use of electronic medical record (EMR) data in analysis of association between KRAS mutations and depression in colorectal cancer patients.. Journal of Clinical Oncology, 2018, 36, 861-861.	1.6	0
79	Cutaneous adnexal adenocarcinoma with exquisite sensitivity to trastuzumab. Head and Neck, 2017, 39, E69-E71.	2.0	8
80	Trends in the Incidence and Outcomes of Hospitalized Cancer Patients With Clostridium difficile Infection: A Nationwide Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 466-472.	4.9	22
81	An Analysis of Individual Body Fat Depots and Risk of Developing Cancer. Mayo Clinic Proceedings, 2017, 92, 536-543.	3.0	9
82	Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. Journal of Surgical Oncology, 2017, 116, 83-88.	1.7	24
83	Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Investigational New Drugs, 2017, 35, 180-188.	2.6	647
84	Promise of Wearable Physical Activity Monitors in Oncology Practice. Journal of Oncology Practice, 2017, 13, 82-89.	2.5	77
85	Oncology Nursing Perceptions of Patient Electronic Portal Use: A Qualitative Analysis. Oncology Nursing Forum, 2017, 44, 165-170.	1.2	10
86	Utilization of palliative care in intubated patients with metastatic cancer: A 10-year nationwide analysis.. Journal of Clinical Oncology, 2017, 35, 69-69.	1.6	0
87	Exploring the association between KRAS mutations and depression in non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2017, 35, 114-114.	1.6	0
88	Plasma Leptin Levels and Risk of Incident Cancer: Results from the Dallas Heart Study. PLoS ONE, 2016, 11, e0162845.	2.5	10
89	Quantification of renal steatosis in type II diabetes mellitus using dixon-based MRI. Journal of Magnetic Resonance Imaging, 2016, 44, 1312-1319.	3.4	27
90	A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 577-584.	2.3	12

#	ARTICLE	IF	CITATIONS
91	Premorbid body mass index and mortality in patients with lung cancer: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2016, 102, 49-59.	2.0	45
92	A Variant in PNPLA3 Associated With Fibrosis Progression but not Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 295-300.	4.4	31
93	A Prospective Analysis of Plasma Adiponectin and Risk of Incident Cancer: The Dallas Heart Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 873-878.	4.9	7
94	Impact of Diabetes Mellitus on the Outcome of Pancreatic Cancer. <i>PLoS ONE</i> , 2014, 9, e98511.	2.5	11
95	Yttrium-90 Radioembolization of Hepatic Metastases from Colorectal Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 120.	2.8	38
96	Cost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy for Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 773-783.	0.8	18
97	The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 325-334.	0.4	270
98	Pathologic complete response rates after neoadjuvant chemoradiation (CRT) for rectal cancer: Do novel agents have a role?. <i>Journal of Clinical Oncology</i> , 2012, 30, 597-597.	1.6	1
99	Pathological complete response rates after neoadjuvant chemoradiation (CRT) for rectal cancer: Do novel agents have a role?. <i>Journal of Clinical Oncology</i> , 2012, 30, e14165-e14165.	1.6	4